Junlin Li

Dr. Junlin Li

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Cancer Cell
Verified
Journal Article
Closed access
JSJian Shi
Jian Shi
YWYifan Wang
Yifan Wang
LZLei Zeng
Lei Zeng
YWYadi Wu
Yadi Wu
JDJiong Deng
Jiong Deng
BZBinhua Zhou
Binhua Zhou

13 April 2010 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
YLYiwei Lin
Yiwei Lin
YWYadi Wu
Yadi Wu
JLJunlin Li
Junlin Li
CDChenfang Dong
Chenfang Dong
XYXiaofeng Ye
Xiaofeng Ye
BZBinhua Zhou
Binhua Zhou
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 February 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JLJunlin Li
Junlin Li
BZBinhua Zhou
Binhua Zhou
Epithelial-mesenchymal transition (EMT) not only confers tumor cells with a distinct advantage for metastatic dissemination, but also it provides those cells with cancer stem cell-like characters for proliferation and drug resistance. However, the molecular mechanism for maintenance of these stem cell-like traits remains unclear.

13 February 2019 in Biomarkers
Verified
Journal Article
Closed access
YWYufei Wu
Yufei Wu
ZWZhibin Wang
Zhibin Wang
XJXueping Jia
Xueping Jia
HZHuan Zhang
Huan Zhang
HZHong Zhang
Hong Zhang
KZKejin Zhang
Kejin Zhang
Background: The serum lipid profile has become a routine clinical test and used as an important predictor for Alzheimer’s disease (AD), although its predictive value remains undetermined. Objective: To evaluate the role of serum lipid levels in predicting the risk of AD. Methods: Meta-analyses were conducted using Comprehensive Meta-analyses (CMA) software to investigate the association between four conventional serum lipid profile parameters and the risk of AD, focused on samples from Asian. Results: In total, 3423 AD patients and 6127 healthy participants were involved. The results demonstrated that AD patients showed higher LDL-C and TC levels (SMD = 0.27, 95% CI: 0.04 ∼ 0.51, P = 0.02 for LDL-C; SMD = 0.25, 95% CI: 0.05 ∼ 0.46, P = 0.02 for TC) compared with those of healthy controls. People with higher LDL-C and/or TC levels had an increased risk of AD (OR = 1.64, 95% CI: 1.07 ∼ 2.51 for LDL-C and OR = 1.58, 95% CI: 1.10 ∼ 2.92 for TC). Conclusions: This study provided evidence that serum LDL-C and TC levels were associated with the risk of AD in Asian individuals. The routine lipid profile may be useful for Alzheimer’s disease (AD) diagnosis, monitoring and treatment.

20 February 2013 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
JLJunlin Li
Junlin Li
GZGuifang Zhao
Guifang Zhao
XGXiaocai Gao
Xiaocai Gao
Neurodevelopmental disorders are classified as diseases that cause abnormal functions of the brain or central nervous system. Children with neurodevelopmental disorders show impaired language and speech abilities, learning and memory damage, and poor motor skills. However, we still know very little about the molecular etiology of these disorders. Recent evidence implicates the bromodomain-containing proteins (BCPs) in the initiation and development of neurodevelopmental disorders. BCPs have a particular domain, the bromodomain (Brd), which was originally identified as specifically binding acetyl-lysine residues at the N-terminus of histone proteinsin vitroandin vivo. Other domains of BCPs are responsible for binding partner proteins to form regulatory complexes. Once these complexes are assembled, BCPs alter chromosomal states and regulate gene expression. Some BCP complexes bind nucleosomes, are involved in basal transcription regulation, and influence the transcription of many genes. However, most BCPs are involved in targeting. For example, some BCPs function as a recruitment platform or scaffold through their Brds-binding targeting sites. Others are recruited to form a complex to bind the targeting sites of their partners. The regulation mediated by these proteins is especially critical during normal and abnormal development. Mutant BCPs or dysfunctional BCP-containing complexes are implicated in the initiation and development of neurodevelopmental disorders. However, the pathogenic molecular mechanisms are not fully understood. In this review, we focus on the roles of regulatory BCPs associated with neurodevelopmental disorders, including mental retardation, Fragile X syndrome (FRX), Williams syndrome (WS), Rett syndrome and Rubinstein-Taybi syndrome (RTS). A better understanding of the molecular pathogenesis, based upon the roles of BCPs, will lead to screening of targets for the treatment of neurodevelopmental disorders.

27 January 2014 in RSC Advances
Verified
Journal Article
Closed access
PDF file
JLJunlin Li
Junlin Li
XAXueqin An
Xueqin An
ZPZhengfeng Pan
Zhengfeng Pan
LSLianmei Sun
Lianmei Sun
Fluorescent silver nanoparticles (AgNPs) were embedded in the bilayer of liposomes and acted as a photothermic switch for photoinduced drug release.